# Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients

> **NCT02201459** · PHASE3 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 200 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Nilotinib (Tasigna ®), capsules of 150 mg
- **DRUG:** Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)

## Key facts

- **NCT ID:** NCT02201459
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2022-10
- **Final completion:** 2022-10
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02201459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02201459, "Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02201459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*